Phage Therapy Market Know the Scope and Trends

"Phage Therapy Market" is poised to grow at a CAGR of 18.29% from 2024 to 2031 according to a new report by InsightAce Analytic.

Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1094

Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global phage therapy market are:
• Shift toward personalized healthcare
• Rising number of patients
• Rising incidence of infectious diseases

The following are the primary obstacles to the phage therapy market's expansion:
• Absence of comprehensive clinical information
• Lack of clarity about the policies
• Increasing worry about microorganisms that are resistant to antibiotics

Future expansion opportunities for the global phage therapy market include:
• Increased investment funding by major market participants
• Growing innovative pharmaceuticals
• Accelerating research and development efforts

Market Analysis:
Phage therapy has proven effective in treating multiple bacterial infections, including those caused by Escherichia coli, Pseudomonas, and Staphylococcus species. This success has led to significant advancements in the application of phage therapy across various medical and therapeutic fields.

Additionally, phages hold potential for use in human biotherapy and environmental decontamination. Research has also demonstrated that phage therapy can serve as an innovative antimicrobial approach to combat antibiotic resistance. The growing prevalence of bacterial infections is expected to drive the demand for phage therapy as a viable alternative to conventional antibiotics.

List of Prominent Players in the Phage Therapy Market:
• Armata Pharmaceuticals, Inc.
• Adaptive Phage Therapeutics
• AmpliPhi Biosciences
• BiomX (MBcure Ltd.)
• C3J Therapeutics
• Enbiotix
• Eligo Bioscience
• Intralytix, Inc.
• InnoPhage
• iNtODEWorld
• Locus Biosciences
• MicroPhage, Inc.
• Phage International
• PhagoMed Biopharma GmbH
• Pherecydes Pharma SA
• TechnoPhage
• Phagelux
• SNIPR BIOME
• Microgen Russia

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/1094

Recent Developments:
• In January 2024, Adaptive Phage Therapeutics, Inc., a biotechnology company in the clinical stage, announced that the first patient had been dosed in the PHAGE clinical study. This study evaluates the efficacy of bacteriophage therapy in adults with cystic fibrosis who carry Pseudomonas aeruginosa in their lungs.
• In March 2024, BiomX Inc. and Adaptive Phage Therapeutics, Inc. announced they had entered into a definitive merger agreement. BiomX is a clinical-stage company that studies and develops natural and engineered phage therapies that target specific pathogenic bacteria.
• In January 2024, Technophage, a biopharmaceutical business that focuses on developing and producing biologics, namely those derived from bacteriophages, officially announced the successful dosing of the first patient in this critical stage. This clinical trial (ID: NCT05948592) is to determine if TP-102 is effective in treating diabetic foot ulcers caused by Staphylococcus aureus, Pseudomonas, and Acinetobacter baumannii.

Phage Therapy Market Dynamics:
Market Drivers: Rising Incidence of Infectious Diseases
The growing incidence of infectious diseases worldwide is a key factor driving interest and innovation in phage therapy. This treatment approach utilizes bacteriophages-viruses capable of targeting and eliminating bacterial infections. The increasing emergence of antibiotic-resistant bacteria, largely due to the overuse and misuse of traditional antibiotics, has rendered conventional treatments less effective. As a result, the demand for alternative therapies such as phage therapy is rising. Additionally, the growing number of research studies and clinical trials exploring the efficacy of phage therapy for bacterial infections is further propelling market growth.

Challenges: Lack of Clarity Regarding the Policies and Procedures
Unlike antibiotics, phage therapy lacks a well-defined regulatory framework, creating uncertainty in approval processes and market entry. The absence of standardized guidelines can pose challenges for companies and researchers attempting to develop and commercialize phage-based treatments. Additionally, limited public awareness and hesitation in accepting the concept of using viruses to combat bacterial infections may hinder the widespread adoption of phage therapy, restraining market expansion.

North America is Expected to Grow with the Highest CAGR During the Forecast Period
North America is expected to lead the phage therapy market, registering a substantial revenue share and demonstrating a high compound annual growth rate (CAGR) over the forecast period. The region's well-established healthcare infrastructure, robust investment in research and development, and favorable regulatory support contribute to its leadership in this field. Increased funding, a deeper understanding of phage biology, and advancements in developing phage-based therapeutics are anticipated to drive market growth across North America in the coming years.

Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1094

Segmentation of Phage Therapy Market-
By Therapeutic Area-
• Infectious Diseases
• Oncological Disorders
• Other Disorders
By Route of Administration-
• Oral
• Topical
• Rectal
• Intravenous
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Get more information: @
https://www.insightaceanalytic.com/report/global-phage-therapy-market-/1094

Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG

This release was published on openPR.